Genesis. 1. Absence of Provisions on the Recognition of Arbitration Agreements in Preparatory Drafts Article II is probably the article with the most turbulent drafting history. 6 Although the preliminary work for the Convention spanned more than five years, the incorporation of provisions on the recognition of arbitration agreements was not discussed before the first day of the Conference, i.e. less than three weeks before adoption of the Convention. Initially, neither the 1953 ICC draft1 nor the 1955 draft of the UNCITRAL Committee on the Enforcement of International Arbitral Awards2 dealt with the recognition of arbitration agreements.
Genesis. GEneral NEural SImulation System. Available online at thhp://xxx.xxxxxxx-xxx.xxx (retrieved Ocotber 2013) Gewaltig M-O & Xxxxxxxx M. (2007) NEST (Neural Simulation Tool) Scholarpedia 2(4):1430.
Genesis. GENESIS ACOUSTICS is a high-tech company founded in 1999 (SME), spin-off from CNRS-LMA. Its main activities are Sound Simulation, Sound Perception, and Sound Design and its main markets are the automotive (Renault, PSA, Volkswagen, Hyundai, Nissan, etc.) and the aeronautic industries (Airbus, Eu- rocopter, Dassault Aviation, Snecma, etc.). GENESIS spends more than 30 % of its activities in Research and Development projects (FUI, EC FP7 projects). GENESIS received an Award from the SFA (Société Française d’Acoustique) in 2005 for its technologies and involvement in research projects. The key know- hows of GENESIS are: • Signal Processing, software development, real-time sound simulators • 3D sound and virtual reality • Psychoacoustics • Speech intelligibility Among other realizations, GENESIS has developed LEA, a tool for sound quality assessment and sound design used by Dassault, Airbus, Snecma, Eurocopter. GENESIS was also expert on EC FP7 project, formerly SEFA and now COSMA (Xxxxxxx Xxxxxxxx), about the sound simulation of aircraft and sound perception for community around airports. Key staff Xxxxxxx Xxxxxxxx (Local Manager) is the executive director and founder of GENESIS. He re- ceived master’s degree in engineering from l’École Nationale des Arts and a master’s degree in acous- tics from the University of Aix-Marseille (1991). He has worked with the Laboratoire de Mécanique et d’Acoustique (LMA) du CNRS and for real-time sound simulation. Xxxxxxxxxx Xxxxxxxx is the technical director of GENESIS. He received a PhD degree in acoustics from the Université du Maine (1997, physical modeling of boards). He has worked for several acoustical engi- neering agencies and joined GENESIS in 2008. His specialties include signal processing, sound perception, microphone array design, speech intellegibillity. Xxxxxxxxx Xxxxxxxx received a Ph.D in Acoustics from the Université du Maine (Le Mans) in 2004. Since 2000, he has been involved in several projects with IRCAM. He has worked with the department of Psychology at Carnegie Mellon University (Pittsburgh, PA) and with Davide Rocchesso at IUAV. His research activities include psychoacoustics, perception and cognition of sound sources, and vocal imitations of sounds.
Genesis. 11.2.1.1 Verizon will provide an appropriate EMI record to Genesis; and
Genesis. Develop, implement and evaluate GMP procedures for the large scale production of TIL suitable for infusion into patients with metastatic melanoma. - Consult with the FDA to determine the appropriate clinical trial design necessary to secure approval for the commercial development of TIL therapy for patients with metastatic melanoma and sponsor the IND for this new clinical protocol Serve as the coordinating center for the multicenter licensing clinical trial. - Supply TIL in sufficient quantities to the NCI Surgery Branch and other multicenter sites to complete the planned clinical trials (including the licensing trial) needed for FDA approval of ACT/TIL. Support the establishment of a central facility for the processing and provision of TIL for the studies under this CRADA. Surgery Branch, NCI and Genesis - Develop SOP for large scale TIL growth, selection and testing to support the FDA approval of the ACT/TIL therapy approach. Attend joint meetings with the FDA to define the exact format and criteria needed in the clinical trial(s) to obtain FDA approval. - Develop, conduct and evaluate a multiinstitutional clinical trial (to include the NCI Surgery Branch as a clinical trial site) for patients with metastatic melanoma treated with TIL that can be used as a licensing trial required for FDA approval and subsequent commercialization of ACT/TIL. PHS ICT-CRADA Case Ref. No. _______ MODEL ADOPTED June 18, 2009 - Exchange information and expertise to further the successful development of TIL therapy for patients with metastatic melanoma. Related NCI and Collaborator Agreements: None Related Intellectual Property and Business/Scientific Expertise of the Parties NCI Surgery Branch
Genesis. Genesis recognizes and acknowledges that it has in the past, currently has, and prior to the Effective Time will have, access to certain confidential information of Company, such as lists of customers, operational policies, pricing and cost policies that are valuable, special and unique assets of Company and Company's business. Genesis agrees that it will not disclose any confidential information to any person, firm, corporation, association, or other entity for any purpose or reason whatsoever, prior to the Effective Time without prior written consent of Stockholder. In the event of a breach or threatened breach by Genesis of the provisions of this Section 7.12, Stockholder shall be entitled to an injunction restraining Genesis from disclosing, in whole or in part, such confidential information. Nothing contained herein shall be construed as prohibiting Stockholder from pursuing any other available remedy for such breach or threatened breach, including the recovery of damages.
Genesis agrees to an extension of the deadline for Findex to register its shares of stock to August 15, 2001 as described in Paragraph 8(c) of the Settlement Agreement.
Genesis. Genesis Energy, L.P.
Genesis. Genesis is an aviation company that acquires and leases commercial jet aircraft and other aviation assets. Genesis' aircraft are leased under long-term contracts to a diverse group of airlines throughout the world. Genesis, a Bermuda exempted company, has its registered office at Clarendon House, 0 Xxxxxx Xxxxxx, Xxxxxxxx XX 00, Bermuda. Although Genesis is organized under the laws of Bermuda, it is a resident in Ireland for Irish tax purposes and thus is subject to Irish corporation tax on its income in the same way, and to the same extent, as if it were organized under the laws of Ireland. Genesis' principal executive offices are located at 0000 Xxxxxxxx Xxxxxx, Xxxxxxxx, Xxxxxxx, Co. Xxxxx, Ireland, and its general telephone number is +000 00 000 000. As of September 30, 2009, Genesis had total shareholders' equity of $488 million and total assets of $1.8 billion. Each Genesis common share, par value $0.001 (a "Genesis Common Share"), has been issued in the form of an American Depositary Share (a "Genesis ADS"). Genesis ADSs are quoted on the NYSE under the ticker symbol "GLS" Table of Contents and, as of February 4, 2010, the last practicable date prior to the date of this proxy statement/prospectus, the closing stock price of Genesis ADSs on the NYSE was $8.15 and Genesis had a market capitalization of approximately $280 million. The Genesis Special General Meeting (page 108) Genesis will hold a special general meeting of its shareholders (the "Genesis Special General Meeting") on March 23, 2010, at 11:00 a.m., Irish Time, at 0000 Xxxxxxxx Xxxxxx, Xxxxxxxx, Xxxxxxx, Co. Xxxxx, Ireland. Genesis shareholders will be asked at the Genesis Special General Meeting to: • adopt the Amalgamation Agreement and approve the Amalgamation; • approve an adjournment of the Genesis Special General Meeting for the solicitation of additional proxies in favor of the above proposal, if necessary; and • transact such other further business, if any, as may lawfully be brought before the meeting. All Genesis Common Shares are currently held as Genesis ADSs. If you are a holder of record of Genesis ADSs, meaning that your Genesis ADSs are represented by Genesis ADRs or book entries in your name so that you appear as a Genesis ADS holder in the register maintained by Deutsche Bank Trust Company Americas, the depositary for the Genesis ADSs (together with any successor or assignee thereof, the "Depositary"), you will receive a voting card from the Depositary with instructions o...
Genesis. Citi performed a discounted cash flow analysis of Genesis to calculate the estimated present value of the standalone after-tax free cash flows that Genesis was forecasted to generate during calendar years 2009 through 2013 based on internal estimates of Genesis' management and certain third party appraisals with respect to the aircraft assets and inventory of Genesis provided to Citi by Genesis' management. Estimated terminal values for Genesis were calculated based on the assumption that Genesis' portfolio of assets would be sold in December 2013 at a price equal to 90% to 100% of the appraised estimated future base values of such assets. The cash flows and terminal values were then discounted to present value as of June 30, 2009 using discount rates ranging from 17% to 21%.
